Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Colonic Neoplasms × bexmarilimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Gastrointestinal 1

Conditions

Sarcoma 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

Oxaliplatin 15 Fluorouracil 12 Irinotecan 11 Leucovorin 10 Bevacizumab 8 pembrolizumab 7 Cetuximab 7 Capecitabine 6 Nivolumab 5 Cyclophosphamide 5 fludarabine 4 aldesleukin 4 Panitumumab 4 Folfox protocol 4 oblimersen 3 Gemcitabine 3 selpercatinib 2 poly ICLC 2 labetuzumab 2 dehydroftorafur 2 conatumumab 2 bintrafusp alfa protein, human 2 Receptor Protein-Tyrosine Kinases 2 Levoleucovorin 2 Interleukin-2 2 Gefitinib 2 Erlotinib Hydrochloride 2 Drug Therapy 2 Chemotherapy, Adjuvant 2 BCG Vaccine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05104905 2022-05-11

RENACOL

Faron Pharmaceuticals Ltd

Phase 1/2 Withdrawn

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡